

Implications of the ESMO Availability Survey for WHO's Cancer control policies

Andreas Ullrich WHO

ESMO Congress 2014 Madrid



**World Health
Organization**

Overview

- Political context and the NCD framework
- Knowledge about barriers
- Access framework
- What next?



World Health
Organization

Access to NCD essential medicines on the global agenda

- UN Political Declaration on NVD 2011
- Global Coordinating Mechanism (2014):
 - working group on access to medicines and health technologies
- UN Interagency Taskforce on NCDs (2014)
- Universal Health Coverage and Post 2015 agenda

WHO's global NCD control Framework

Surveillance
Mapping the
epidemic of
NCDs



Prevention
Reducing the
level of
exposure to
risk factors




Management
Strengthen
health care for
people with
NCDs



World Health
Organization

Monitoring Framework



World Health
Organization

Global Monitoring Framework Target 9

- An 80% availability of the affordable basic technologies and essential medicines, including generics, required to treat major non communicable diseases in both public and private facilities



World Health
Organization

Determinants for access

- Availability
- Affordability (Price)
- Procurement practice
- Distribution practice
- Provision of care




Barriers to Access: prices

Table 1 – Prices of cancer medicines in Ghana and brand premium

Name of medicine and formulation	Price US\$		Premium
	Generic	(Brand name)	
Adriamycin 50mg	3.13	712.00 (Myocet®)	227.8
Anastrozole 1 mg (28 tabs)	103.13	108.02 (Arimidex®)	1.0
Bevacizumab 100 mg	-	947.92 (Avastin®)	N/A
Bicalutamide 150 mg (28 tabs)	26.25	375.00 (Casodex®)	14.3
Bortezomib inj. 3.5 mg	-	2,005.21 (Velcade®)	N/A
Docetaxel Inj 20 mg	49.58	166.67 (Taxotere®)	3.4
Docetaxel Inj 80 mg	135.94	657.81 (Taxotere®)	4.8
Tamoxifen 20 mg	14.84	15.63 (Nolvadex®)	1.1
Trastuzumab 120's	-	4,322.92 (Herceptin®)	N/A
Vincristine Inj 1 mg	4.17	22.16 (Oncovin®)	5.3
Vinorelbine Inj 50mg/5ml	106.77	218.72 (Navelbine®)	2.0
Zoledronic acid Inj 4 mg	85.94	286.41 (Zometa®)	3.3

Access to essential medicines

A Framework for action



Options to improve the situation

- **Rational selection**

- Standard Therapeutic Guidelines including evidence-based selection of medicines (NEML based on recommendations from WHO Expert Committee on Selection and Rational Use)

- **Financing and Universal Health Coverage**

- Increase government budget to ensure widespread access to a reduced number of NCD essential medicines
- Expand coverage/health insurance and ensure NCD essential medicines are part of the essential package covered

Options to improve the situation

● Price

- Competition, promotion of generics, transparent procurement procedures, substitution, reduce duties/taxes and mark-ups, monitoring prices
- For single source products or under patent, apply WTO/TRIPS flexibilities and use available differential pricing

● Reliable Supply systems

- Supply quality-assured products:
- Improve quantification of needs and forecasting using good information systems
- Reinforce private and public supply chains



World Health
Organization

Access survey > precondition for changes

- WHO:
 - Fit in WHO's work on reviewing access to NCD medicines
 - Basis for Global Coordination Mechanism on NCD and its working group on access to medicines .
- Governments: precondition for national priority setting in procurement policies
- NGOs: food for advocacy



World Health
Organization